Competitive Technologies

Competitive Technologies' Calmare Pain Therapy Device Featured on the Emmy Award Winning Program "The Doctors"


Fairfield, CT -- (SBWIRE) -- 06/13/2014 -- Competitive Technologies, Inc.,(CTI) the pain mitigation company, today announced that the Emmy® award winning TV program “The Doctors” recently featured a medical case involving a young patient living with Complex Regional Pain Syndrome (CRPS) – a long-term chronic disease characterized by severe chronic pain, swelling, and changes in the skin that often worsens over time.

The show featured CTI’s flagship product, the Calmare® Pain Therapy device, as a non-invasive pain therapy solution alternative instead of the large host of medicines that Matthew currently uses to address the debilitating pain from CRPS.

About the Segment on “Matthew” and CRPS

The segment centered on the case of Matthew, the teenage son of Inside Edition Chief Correspondent Jim Moret. Matthew sustained a foot injury while playing soccer as a young child that progressed into CRPS. His doctors have prescribed a large host of pain medications, including LYRICA® (Pregabalin) and CYMBALTA® (Duloxetine). In addition, Matthew has tried the gamut of alternative therapies, such as acupuncture and Reiki, the Japanese stress reduction technique involving the “laying of hands.” To date, no treatment has adequately treated his chronic pain condition.

In their continuing effort of finding a better solution for CRPS, the Moret family came to the show’s studio’s seeking advice from their panel of doctors. In the episode, Dr. Travis Stork, M.D., an Emmy® -nominated co-host of the award-winning talk show and a practicing board-certified emergency medicine physician, offered the family the opportunity to learn more about Calmare, a non-narcotic, non-invasive procedure for the treatment of chronic pain. Through a telephone link up with Dr. Jack D’Angelo, M.D., a New York City based physical medicine and rehabilitation specialist at Calmare Pain Relief Solution, he offered some insights on how Calmare Therapy works: “The Calmare device produces a ‘no pain’ message, which is then transmitted to the affected nerve through disposable surface electrodes that are applied to the skin surrounding the region of the patient’s pain. After completion of multiple treatments, many patients are able to experience long-lasting relief.”

As a follow-up, Dr. Stork offered Matthew an opportunity to be seen by one of the many centers in the U.S. now offering Calmare Therapy to their patients.

To view the segment, please visit:

About Competitive Technologies Inc.
Competitive Technologies Inc., the pain mitigation company, develops and commercializes innovative wound and pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare® Pain Therapy Device, which grants it an exclusive right to sell, market, research and develop the medical device. The Company is the exclusive licensed global distributor of Calmare.

Forward-Looking Statement
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.